Progenity, Inc.

PROG

Net income
-233
millions, $
Market cap
386
millions, $
EBITDA
-156
millions, $
Revenue
65.2
millions, $
P/E
N/A
Revenue Growth
N/A
% year on year
Dividends

Estimation

0
% per year
About

Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages.

Progenity, Inc.

1. There may be a delay in updating the share price

The information on Dastocks.com is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy, or in any other way. Dastocks will not accept liability for any loss or damage, including without limitation any loss of profit, which may arise directly or indirectly from use of or reliance on the information on Dastocks.com. The Authors may buy and sell securities before and after any particular article and/or information herein is published.

You must accept the terms and conditions if you wish to continue to use the Dastocks website.